Analyst Price Targets — ALT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 27, 2026 9:11 pm | — | Barclays | $20.00 | $6.18 | TheFly | Altimmune initiated with an Overweight at Barclays |
| April 2, 2024 6:42 am | Patrick Trucchio | H.C. Wainwright | $12.00 | $10.23 | StreetInsider | Altimmune (ALT) PT Lowered to $12 at H.C. Wainwright following Q4 report |
| December 1, 2022 5:36 am | — | Goldman Sachs | $20.00 | $9.95 | Benzinga | Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20 |
| November 11, 2022 8:29 am | — | JMP Securities | $26.00 | $11.12 | Benzinga | JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $26 |
| August 31, 2022 11:00 am | — | Jefferies | $35.00 | $22.08 | Benzinga | Jefferies Maintains Buy on Altimmune, Raises Price Target to $35 |
| August 30, 2022 8:40 pm | Yasmeen Rahimi | Piper Sandler | $25.00 | $18.94 | TheFly | Altimmune management confident on NAFLD Phase 1b study, says Piper Sandler |
| August 17, 2022 6:36 am | — | H.C. Wainwright | $50.00 | $17.66 | Benzinga | HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $50 |
Latest News for ALT
Altimmune and Novo Nordisk have encountered some headwinds in recent years. Both could rebound, but one of them looks far more likely to do so.
GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026.
Acting CEO Tony Isaac Outlines Compliance Restoration, Governance Strengthening, and Strategy to Drive Long-Term Stockholder Value LAS VEGAS, NEVADA / ACCESS Newswire / February 23, 2026 / ALT5 Sigma Corporation (the "Company" or "ALT5") (NASDAQ:ALTS)(FRA:5AR1), a fintech company operating institutional-grade global payments, trading, and settlement infrastructure, today issued a letter to stockholders from Tony…
Appointment strengthens ALT5's Board with expertise across AI infrastructure, decentralized systems, and global technology governance LAS VEGAS, NEVADA / ACCESS Newswire / February 12, 2026 / ALT 5 Sigma Corporation (the "Company" or "ALT5") (NASDAQ:ALTS)(FRA:5AR1), a fintech company operating institutional-grade global payments, trading, and settlement infrastructure, today announced the appointment of Dr. Adel…
Altimmune, Inc. (NASDAQ: ALT - Get Free Report)'s stock price was up 7.2% during mid-day trading on Friday. The company traded as high as $5.48 and last traded at $5.4650. Approximately 2,268,356 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 6,454,089 shares. The stock had previously closed
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALT.
U.S. House Trading
No House trades found for ALT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.